Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.6751 +0.0041 (+0.61%)
Streaming Delayed Price Updated: 10:41 AM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action
From Robbins LLP
Via Business Wire
News headline image
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Nick Tressler as Chief Financial Officer
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in Stifel Healthcare Conference 2025
From Vistagen
Via Business Wire
News headline image
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Paul Edick to its Board of Directors
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at The Menopause Society 2025 Annual Meeting
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
News headline image
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the BTIG Virtual Biotechnology Conference
From Vistagen
Via Business Wire
News headline image
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
From Vistagen
Via Business Wire
News headline image
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
From Vistagen
Via Business Wire
News headline image
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
From Vistagen
Via Business Wire
News headline image
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
From Vistagen
Via Business Wire
News headline image
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
From Vistagen
Via Business Wire
News headline image
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
From Vistagen
Via Business Wire
News headline image
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
News headline image
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
From Vistagen
Via Business Wire
News headline image
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
From Vistagen
Via Business Wire
News headline image
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
From Vistagen
Via Business Wire
News headline image
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.